Study Shows Risks of Anxiety and Depression After Cardiac Device Implantation
April 26, 2021 Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference this week, an online scientific congress of the European Society of Cardiology (ESC).[1]
“Most patients adapt well to living with an ICD. For others it completely changes their life, with worries about shocks from the device, body image, and livelihood as some need to change their job,” said study author Professor Susanne Pedersen of Odense University Hospital, Denmark.
Previous studies have shown that anxious or depressed ICD patients have poorer quality of life and increased risks of arrhythmias and death.[2,3,4] This study examined how many patients develop anxiety or depression after ICD implantation, as screening tends to be a one-time event.
Journal of the American College of Cardiology)
Stroke survivors trying to regain arm function in rehabilitation found incremental improvement with vagus nerve stimulation in the VNS-REHAB trial. (
The Lancet)
The American College of Physicians released a guideline on the use of point-of-care ultrasound for patients with acute dyspnea.
A theory posits that dual SGLT1 and SGLT2 inhibition could improve cardiovascular outcomes for people with diabetes. (
Circulation)
Philips Stellarex paclitaxel drug-coated balloon did not increase deaths at 5 years over percutaneous transluminal angioplasty in a 600-patient meta-analysis supporting its safety.
Clotting drug tranexamic acid did not raise complication rates for high-risk patients undergoing orthopedic surgeries. (
Keeping Pace: His-Bundle CRT Impresses in 2nd Randomized Trial medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Experts develop quality indicators for management and outcomes of adults with atrial fibrillation
Management and outcomes of adults with atrial fibrillation are presented today at EHRA 2021, an online scientific congress of the European Society of Cardiology (ESC). The document is published in EP Europace, a journal of the ESC.
Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million people globally. Those with the disorder have increased risks of complications including stroke, heart failure and dementia, and are twice as likely to be admitted to hospital as their peers without the condition. The economic burden of atrial fibrillation is rising, mainly due to complications and hospitalisations. Effective therapies exist (e.g. to prevent stroke) but are not consistently used.
(0)
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48
ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date
Data presented at the annual scientific meeting of the European Heart Rhythm Association
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA